A laboratory can run flawless science and still struggle financially if its billing breaks down. Laboratory revenue cycle management (RCM) is the end-to-end process of getting accurately paid for the testing a lab performs — from confirming coverage before a sample is even drawn, through coding and claim submission, to working denials and posting payment. For genetic and molecular labs in particular, RCM is unusually demanding.
The short version
- Lab RCM is the full cycle from verifying coverage to posting final payment for testing performed.
- Key stages: eligibility and prior authorization, coding (CPT/ICD, plus Z-codes for molecular), claim submission, denial management, appeals, and payment posting.
- “Clean claims” — accurate and complete on first submission — are the single biggest lever for getting paid faster.
- Genetic and molecular tests are uniquely hard to bill due to high cost, prior authorization, and programs like MolDx — which is why billing should start at the order.
What is laboratory revenue cycle management?
Revenue cycle management is everything a laboratory does to capture, manage, and collect revenue for the tests it performs. It begins before the specimen arrives — when coverage and medical necessity should be confirmed — and ends when the claim is fully resolved and payment is posted. The science and the billing are tightly coupled: an order that is technically correct but missing the right diagnosis code, prior authorization, or coverage confirmation can produce a perfect result that never gets reimbursed. RCM is the discipline of making sure clinically valid work is also financially recoverable.
The laboratory revenue cycle, stage by stage
1. Eligibility and prior authorization
Before testing, the lab should confirm active coverage and that the plan will pay for the ordered test. Many higher-cost tests also require prior authorization— explicit payer approval obtained in advance. A denial for “no prior authorization” is often difficult to reverse after the fact.
2. Coding: CPT, ICD, and Z-codes
Once a test is performed, it must be translated into standardized codes payers understand:
- CPT codes describe the procedure or test performed.
- ICD codes describe the diagnosis, establishing medical necessity.
- Z-codes (the DEX Z-Code identifiers used in molecular testing programs) identify a specific molecular assay with more granularity than a CPT code alone.
3. Claim submission
The coded claim is submitted to the payer, typically electronically. A claim that is complete, accurate, and properly formatted on the first try is called a clean claim — the heart of an efficient revenue cycle. The cleaner the claim, the faster it adjudicates and the less rework it generates.
4. Adjudication, denials, and appeals
The payer reviews the claim and either pays, adjusts, or denies it. Denials happen for many reasons: eligibility problems, missing prior authorization, coding mismatches, lack of documented medical necessity, or duplicates. Each denial has to be triaged and, where appropriate, corrected and resubmitted or formally appealed. Denial management is labor-intensive, which is exactly why preventing denials upstream pays off so much.
5. Payment posting and patient responsibility
When payment arrives, it is posted against the claim, and any remaining patient responsibility is reconciled and billed. Accurate posting gives the lab a true picture of what it actually collected versus what it billed.
Clean claims: the central lever
A claim that goes out accurate and complete the first time avoids the entire expensive cycle of denial, investigation, correction, and resubmission. Everything upstream — verifying eligibility, securing prior authorization, coding correctly, capturing documentation — exists to maximize clean-claim rates. Labs that treat billing as an afterthought at the end of the process tend to generate more denials; labs that build accuracy in from the start tend to get paid faster and more fully.
Why genetic and molecular tests are uniquely hard
Many molecular and genetic tests are expensive, and payers scrutinize high-dollar claims more closely. Prior authorization is frequently required and varies by payer and test. The MolDx program, administered through certain Medicare Administrative Contractors, sets specific requirements for molecular diagnostic testing, including DEX Z-Code identifiers to precisely identify assays. And molecular coding and coverage policies change, putting a premium on teams and systems that stay current.
| Factor | General lab test | Genetic / molecular test |
|---|---|---|
| Typical cost | Lower | Often substantially higher |
| Prior authorization | Sometimes | Frequently required |
| Coding identifiers | CPT + ICD | CPT + ICD + Z-codes |
| Program-specific rules | Limited | MolDx and similar apply |
| Denial impact per claim | Lower exposure | High exposure per denial |
For labs in this space, dedicated pharmacogenomics and molecular workflows make these requirements far more manageable than generic billing tooling. (For background on PGx itself, see our pharmacogenomics primer.)
Why billing should start at the order
The most expensive billing problems are created — or prevented — at the very beginning of the process. Eligibility, prior authorization, medical necessity, and correct coding are all far cheaper to get right at the point of order than to fix after a denial. When billing intelligence lives at the order step, the lab can catch missing authorizations and gaps before the test runs. That is the philosophy behind order-to-claim systems where the billing layer is connected to the order rather than bolted on afterward — such as Labrynix Billing working alongside the core LIMS. Analytics on denial patterns, supported by tools like Labrynix Intelligence, help labs find and close the leaks. Any AI-assisted analytics should support qualified billing and compliance staff, not replace their review and judgment.
Frequently asked questions
What is a clean claim in lab billing?
A clean claim is one that is accurate, complete, and correctly formatted on first submission, so the payer can adjudicate it without requesting corrections. High clean-claim rates mean faster payment and less costly rework.
Why do genetic tests get denied so often?
Common reasons include missing prior authorization, insufficient documentation of medical necessity, coding mismatches, and program-specific requirements such as MolDx Z-code identifiers. Because these tests are high-cost, payers scrutinize them closely.
What are Z-codes in molecular testing?
Z-codes (DEX Z-Code identifiers) are unique identifiers that specify a particular molecular assay with more granularity than a CPT code alone. They are central to how many molecular tests are tracked and adjudicated, especially under the MolDx program.